Goto, Hideki http://orcid.org/0000-0001-8361-9973
Ito, Satoshi
Kizaki, Masahiro
Yamaguchi, Masaki
Fukuhara, Noriko
Kato, Koji
Saito, Toko
Terui, Yasuhito
Okubo, Sumiko
Soshin, Tomomi
Zeng, Jiewei
Honda, Hideyuki
Badawi, Mohamed
Ross, Jeremy A.
Izutsu, Koji
Funding for this research was provided by:
AbbVie
Article History
Received: 13 September 2023
Accepted: 13 November 2023
First Online: 29 December 2023
Declarations
:
: Venetoclax is being developed in collaboration between AbbVie and Genentech. Ibrutinib is being developed in collaboration between AbbVie and Janssen Research & Development, LLC. The study sponsor funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data, and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Daniel Roybal, PhD, of Bio Connections, LLC, funded by AbbVie.
: Hideki Goto reports lecture fees earned from Kyowa Kirin. Satoshi Ito reports research funding from AbbVie, Amgen, Insight, Novartis, and Zenyaku-Kogyo. Masahiro Kizaki has nothing to declare. Masaki Yamaguchi has nothing to declare. Noriko Fukuhara reports research funding from AbbVie, Bayer, Celgene, Chordia Therapeutics, Chugai, Genmab, Incyte, Kyowa-Kirin, LOXO Oncology, and Takeda. Koji Kato reports research funding from AbbVie, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, and Takeda. Toko Saito has nothing to declare. Yasuhito Terui reports lecture fees earned from AbbVie, Celgene, Chugai, Eisai, Janssen, Ono, and Symbio and a certain contribution from Eisai. Sumiko Okubo reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Tomomi Soshin reports her and her husband’s employment with AbbVie and may hold stock options or other ownership in AbbVie. Jiewei Zeng reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Hideyuki Honda reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Mohamed Badawi reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Jeremy A. Ross reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Koji Izutsu reports advisory board and honoraria fees from AbbVie.